sign free newsletters sign free newsletters merck halts late stage trial verubecestat targeted enzyme involved brain plaque formation reuters staff reuters merck co inc said tuesday halt late stage trial alzheimer drug determined chance working marking latest long line crushing disappointments efforts find effective treatment disease company testing drug verubecestat patients mild moderate alzheimer disease independent data monitoring committee determined virtually chance finding positive clinical effect recommended trial stopped futility news sent merck shares nearly 2 percent hours trading verubecestat belongs class experimental alzheimer drugs called bace1 inhibitors target enzyme involved formation toxic amyloid protein turns plaques brains alzheimer patients